Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06757140 · ClinicalTrials.gov registry record · Phase 1
Opioid Drug Interaction Study
A Phase 1 study of Drug Interactions and Drug Kinetics, sponsored by Shanna Babalonis, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06757140: Recruiting Phase 1 study of Drug Interactions and Drug Kinetics, sponsored by Shanna Babalonis, PhD.
NCT06757140 is a Phase 1 study of Drug Interactions and Drug Kinetics that is actively recruiting participants, run by Shanna Babalonis, PhD. The registered enrollment target is 25 participants, below the 726-participant average among 6 other Drug Interactions trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06757140, a Phase 1 study of Drug Interactions and Drug Kinetics, is actively recruiting participants, sponsored by Shanna Babalonis, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of doses of opioid/placebo and doses of alprazolam/placebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.
Primary Outcome
Participants rated their subjective drug liking on a standardized VAS scale (0 to 100) with higher scores equating to increased liking. Raw data transformed to peak scores.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Alprazolam
- DRUG Oxycodone
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 1 |
What NCT06757140 shows while recruiting
NCT06757140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 726-participant average among 6 other Drug Interactions trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Drug Interactions appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06757140 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06757140 about?
NCT06757140 is a clinical study titled "Opioid Drug Interaction Study". This study will examine the effects of doses of opioid/placebo and doses of alprazolam/placebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from b...
What is the current status of trial NCT06757140?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2025-04-01. Estimated completion is 2029-06-01.
What conditions does trial NCT06757140 study?
This clinical trial studies the following conditions: Drug Interactions, Drug Kinetics.
What interventions are being tested in trial NCT06757140?
The interventions under investigation include: Placebo (DRUG), Alprazolam (DRUG), Oxycodone (DRUG).
Who is sponsoring clinical trial NCT06757140?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06757140 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Interactions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
COMPLETED · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
COMPLETED · Phase 1
-
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
RECRUITING · Phase 4
-
Shared Decision for Drug Interactions in Oral Anticoagulation
RECRUITING · NA
-
Emergency Department (ED) Drug Interaction in Emergency Department Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI